By Bill Wichert ( January 11, 2021, 9:23 PM EST) -- The Third Circuit on Monday revived Fresenius Kabi USA LLC's antitrust claims that Par Pharmaceuticals delayed Fresenius from marketing a generic blood pressure medication due to Par's exclusive ingredient supply arrangements, saying a New Jersey federal court improperly tossed the suit without conducting a requisite patent analysis....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.